Lifesci Capital Upgrades Context Therapeutics (NASDAQ:CNTX) to “Strong-Buy”

Context Therapeutics (NASDAQ:CNTX) was upgraded by equities research analysts at Lifesci Capital to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Other analysts have also recently issued research reports about the stock. HC Wainwright raised their price objective on shares of Context Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. JonesTrading assumed coverage on Context Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price on the stock. Wall Street Zen upgraded Context Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 16th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a research note on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.00.

Context Therapeutics Price Performance

Shares of CNTX opened at $2.28 on Monday. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.85. The company has a market capitalization of $209.49 million, a P/E ratio of -9.50 and a beta of 1.93. The firm’s 50 day simple moving average is $1.80 and its 200 day simple moving average is $1.31.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC purchased a new position in shares of Context Therapeutics in the fourth quarter worth about $43,000. Quadrature Capital Ltd bought a new position in Context Therapeutics during the 4th quarter worth approximately $68,000. Clear Harbor Asset Management LLC grew its position in Context Therapeutics by 60.5% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after acquiring an additional 35,000 shares during the last quarter. XTX Topco Ltd increased its stake in Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after purchasing an additional 91,008 shares during the period. Finally, Citadel Advisors LLC bought a new stake in Context Therapeutics in the third quarter valued at approximately $100,000. 14.03% of the stock is owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.